Next Article in Journal
Annotating Cancer Variants and Anti-Cancer Therapeutics in Reactome
Next Article in Special Issue
A Novel Three-Colour Fluorescence in Situ Hybridization Approach for the Detection of t(7;12)(q36;p13) in Acute Myeloid Leukaemia Reveals New Cryptic Three Way Translocation t(7;12;16)
Previous Article in Journal
Chemoprevention of Breast Cancer: The Paradox of Evidence versus Advocacy Inaction
Previous Article in Special Issue
Mouse Lymphoblastic Leukemias Induced by Aberrant Prdm14 Expression Demonstrate Widespread Copy Number Alterations Also Found in Human ALL
Cancers 2012, 4(4), 1161-1179; doi:10.3390/cancers4041161
Review

The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)

1,* , 1
 and 2,*
Received: 22 August 2012; in revised form: 29 September 2012 / Accepted: 17 October 2012 / Published: 2 November 2012
(This article belongs to the Special Issue Leukemia)
View Full-Text   |   Download PDF [422 KB, uploaded 2 November 2012]
Abstract: Acute myeloid leukemia (AML) is nearly always a fatal malignancy. For the past 40 years, the standard of care remains a combination of cytarabine and an anthracycline known as 7 + 3. This treatment regimen is troubled by both low survival rates (10% at 5 years) and deaths due to toxicity. Substantial new laboratory findings over the past decade have identified many cellular pathways that contribute to leukemogenesis. These studies have led to the development of novel agents designed to target these pathways. Here we discuss the molecular underpinnings and clinical benefits of these novel treatment strategies. Most importantly these studies demonstrate that clinical response is best achieved by stratifying each patient based on a detailed understanding of their molecular abnormalities.
Keywords: acute myeloid leukemia; targeted therapies; early phase trials acute myeloid leukemia; targeted therapies; early phase trials
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Export to BibTeX |
EndNote


MDPI and ACS Style

Assouline, S.; Cocolakis, E.; Borden, K.L.B. The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML). Cancers 2012, 4, 1161-1179.

AMA Style

Assouline S, Cocolakis E, Borden KLB. The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML). Cancers. 2012; 4(4):1161-1179.

Chicago/Turabian Style

Assouline, Sarit; Cocolakis, Eftihia; Borden, Katherine L.B. 2012. "The Development of Novel Therapies for the Treatment of Acute Myeloid Leukemia (AML)." Cancers 4, no. 4: 1161-1179.


Cancers EISSN 2072-6694 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert